Table 2.1 VTE Prophylaxis Inclusion Table

VTE Prophylaxis	Inclusion/Synonyms
Coumadin/Warfarin	Coumadin Jantoven Warfarin Warfarin Sodium
Factor Xa Inhibitor	Arixtra Fondaparinux sodium
Oral Factor Xa Inhibitor	Apixaban1 Betrixaban4 BEVYXXA4 Edoxaban3 Eliquis1 Rivaroxaban2 Savaysa3 Xarelto2
Low Dose Unfractionated Heparin (LDUH) - Include only Heparin given by the subcutaneous (SQ, Subcu, SC, SubQ) route	HEP Heparin Heparin Na Heparin Sod Heparin Sodium Heparin Sodium Inj. Heparin Sodium Inj. Pork Heparin Subcu/SQ/SC/SubQ
Low Molecular Weight Heparin (LMWH)	Dalteparin Enoxaparin Fragmin Innohep Lovenox Tinzaparin
Intermittent Pneumatic Compression Device (IPC)	AE pumps (anti-embolic pumps)-calf/thigh DVT boots-calf/thigh EPC cuffs/ stockings-External pneumatic compression-calf/thigh Intermittent pneumatic compression stockings Intermittent compression device (ICD) Leg pumpers Pneumatic intermittent impulse compression device Rapid inflation asymmetrical compression (RIAC) devices Sequential compression device Sequential pneumatic hose Thrombus pumps-calf/thigh
Venous Foot Pump (VFP)	AE pumps-foot only Foot pump Plantar venous plexus pump-foot only SC boots-foot only SCD boots-foot only Venous foot pump

Note: This table is not meant to be an inclusive list of all available prophylaxis; rather it represents current information available at the time of publication.

^{1 The U.S. Food and Drug Administration (FDA) has approved Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation or to reduce the risk of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) following knee or hip replacement surgery only. It is additionally approved for treatment of DVT and PE and for the reduction in the risk of recurrent DVT and PE following initial therapy.
2 The U.S. Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce the risk of blood clots, deep vein thrombosis (DVT) and pulmonary embolism (PE) following knee or hip replacement surgery only. It is additionally approved: to reduce the risk of stroke in patients with non-valvular atrial fibrillation; for treatment of DVT or PE; to reduce the risk of recurrent DVT and PE following initial treatment.
3 The FDA approved edoxaban (Savaysa) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem. Savaysa has been approved to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already been treated with anti-clotting drug administered by injection or infusion (parenterally), for five to ten days.
4 The U.S. Food and Drug Administration (FDA) has approved betrixaban (BEVYXXA) for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.}

Table 2.6 Qualifiers and Modifiers Table

Note: These guideleines apply only to those data elements that refer to them in their Guidelines for Abstraction Exclusion list(s)

Qualifiers	Modifiers
Qualifiers are words used as adjectives to indicate some uncertainty about whether or not a condition really exists.	Quantitative modifiers are adjectives that quantitatively describe a condition
The following qualifiers should be abstracted as negative findings, unless otherwise specified - Consider this list all-inclusive: And/or (+/-; e.g., "ST abnormalities consistent with ischemia and/or injury"), except when comparing only inclusions (e.g., "ST segment elevation and/or STEMI") Cannot exclude Cannot rule out Could/may/might be Could/may/might have Could/may/might have been Could/may/might have had Could/may/might indicate Or, except when comparing only inclusions Possible Questionable (?) Risk of Rule out (r'd/o, r/o'd) Suggestive of Suspect Suspicious Vs., except when comparing only inclusions Example: If the in-hospital echocardiogram report documents "questionable LVSD", this should be abstracted as a negative finding.	The following quantitative modifiers should be abstracted as negative findings, unless otherwise specified - Consider this list all-inclusive: Borderline Insignificant/not significant/no significant Minor Scant Slight Sub-clinical Subtle Trace Trivial

Table 2.7 Anticoagulation Therapy Table

Anticoagulation Therapy – All Inclusive	Inclusion/Synonyms
Direct Thrombin Inhibitors	Acova Angiomax Angiox Argatroban Bivalirudin Dabigatran Dabigatran etexilate Lepirudin Pradaxa Recombinant Hirudin Refludan
Glycoprotein IIb/IIIa Inhibitor:	Abciximab Aggrastat Eptifibatide Integrilin ReoPro Tirofiban